Ray Co

Ray Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Ray Co (228670.KQ) as of Nov 18, 2026 is -8.68. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -3.26 — a change of 165.92% (lower).

EV/EBITDA

-8.68

YoY

165.92%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Ray Co is 2025 -8.68 . EV/EBITDA (Enterprise Value to EBITDA) of Ray Co was 2024 -3.26 . It decreases by 165.92% lower compared to the previous year.

The Ray Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
12.07 KRW
Jan 1, 2019
4.14 KRW
Jan 1, 2020
10.12 KRW
Jan 1, 2021
19.03 KRW
Jan 1, 2022
5.37 KRW
Jan 1, 2023
6.89 KRW
Jan 1, 2024
-3.26 KRW
Jan 1, 2025
-8.68 KRW
The Ray Co EV/EBITDA history
YEAREV/EBITDAYoY
-8.68+165.92%
-3.26-147.35%
6.89+28.41%
5.37-71.81%
19.03+88.00%
10.12+144.52%
4.14-65.69%
12.07-68.84%
38.73-38.44%
62.91—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ray Co Stock analysis

What does Ray Co do? Ray Co., Ltd. generates revenue through the manufacturing and sale of advanced technology medical devices, focusing on digital diagnostic systems and digital therapy solutions. The company produces dental radiography equipment such as x-ray systems and cone beam computed tomography (CBCT) systems, alongside 3D scanning, dental computer aided design (CAD), and 3D printers for prosthodontics, orthodontics, and implant surgery. Domestic and overseas markets purchase these products, with the company operating through subsidiaries to distribute its offerings globally. Digital diagnostic systems like dental radiography equipment and CBCT systems are sold to healthcare providers and dental clinics, while digital therapy solutions including 3D scanning and CAD systems target dental laboratories and surgical centers. The firm's product portfolio serves both domestic and international clients, leveraging its subsidiaries for global distribution channels. Ray Co., Ltd. emphasizes advanced technology in its medical device offerings, with digital therapy solutions such as 3D printers and CAD systems being key revenue drivers. The company's focus on dental-specific applications ensures targeted sales to specialized healthcare segments, including prosthodontics, orthodontics, and implant surgery practices. Ray Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ray Co stock

EV/EBITDA (Enterprise Value to EBITDA) of Ray Co is -8.68 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Ray Co changed from -3.26 to -8.68, representing a 165.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Ray Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Ray Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Ray Co

All Key Metrics — Ray Co